Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation

Abstract

To evaluate stent-related adverse cardiac events and bleeding complications within 30days after surgical procedures in patients with recent drug-eluting stent (DES) implantation, in whom a bridging protocol was used. In our centre a bridging protocol is used in patients scheduled for cardiac or non-cardiac surgery within 6months after PCI with DES implantation. Clopidogrel and in some cases also acetylsalicylic acid is discontinued 5days prior to the planned intervention and patients are admitted 2 to 3days before the intervention for tirofiban infusion. This is discontinued 4h before intervention. Close postoperative monitoring is performed and double antiplatelet therapy is restarted as soon as possible. Thirty-six consecutive patients were included in the protocol, 15 receiving coronary artery bypass graft and 21 non-cardiac interventions. Thrombotic and bleeding complications were studied for up to 30days after the bridged procedure. No incidences of stent thrombosis or other adverse cardiac events (mortality, myocardial infarction) were seen in up to 30days of follow-up. However, 6 bleeding events were reported of which 5 required a blood transfusion. Our bridging protocol in patients requiring surgery after recent PCI with DES seems adequate to prevent stent thrombosis in this high-risk group. The bleeding risk is not insignificant but in our patient group controllable without major late sequelae. Larger studies should be performed to establish safety and efficacy in order to develop guidelines for these patients.